Interviews With Board Member Lynn Swann Appear On 'Fox & Friends,' 'NY1,' 'TheStreet.com TV,' and 'Your World With Neil Cavuto'
LA JOLLA, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) (www.transdelpharma.com), a specialty pharmaceutical company focused on developing and commercializing non-invasive, topically administered medications, was highlighted during recent interviews with Board Member Lynn Swann on "Fox & Friends," "NY1," "TheStreet.com," and "Your World with Neil Cavuto" on the Fox Business News Channel.
The "TheStreet.com" interview can be viewed at: http://www.thestreet.com/video/10463985/lynn-swann-talks-steelers-politics-biotech.html
In the interview with Gregg Greenberg of "TheStreet.com," Mr. Swann discusses his involvement on the board of the Company as well as their patented transdermal delivery system technology, Transdel(TM). He also highlighted Ketotransdel(R), the Company's lead product, a topical non-steroidal anti-inflammatory drug currently in Phase 3 trial for acute pain. In addition to this lead product, the Company has expanded its product development programs to include cosmetic/cosmeceutical products, which will also utilize the Company's patented transdermal delivery system technology.
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTCBB: TDLP - News) is a specialty pharmaceutical company developing non-invasive, topically-delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(R), the Transdel(TM) cream allows the active ingredient ketoprofen, a non steroidal anti-inflammatory drug, to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the Transdel(TM) platform technology for products in pain management and other therapeutic areas and for cosmetic/cosmeceutical products. For more information, please visit http://www.transdelpharma.com.
Safe Harbor Statement
Statements made in this release that are not historical in nature constitute forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-KSB filed with the SEC on March 26, 2008. Such documents may be read free of charge on the SEC's web site at www.sec.gov. All forward-looking statements included in this release are made as of the date of this press release, and the Company assumes no obligation to update any such forward-looking statements.
For more news and information on Transdel Pharmaceuticals, Inc. please visit www.IRGnews.com/coi/TDLP where you can find the CEO's video, a fact sheet on the company, investor presentations, and more.
|SOURCE Transdel Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved